MedPath

FDA Grants Fast Track Designation to Immuneering's IMM-1-104 for Pancreatic Cancer

• The FDA has granted Fast Track designation to Immuneering's IMM-1-104 for pancreatic ductal adenocarcinoma after one prior line of therapy. • This designation aims to expedite the development and review of IMM-1-104, addressing a critical unmet need in pancreatic cancer treatment. • IMM-1-104 is being developed by Immuneering, a clinical-stage oncology company, for patients who have failed initial treatment regimens. • Immuneering's stock experienced a surge following the announcement, reflecting investor optimism about the drug's potential impact.

Immuneering Corporation (IMRX) saw its shares rise after the Food and Drug Administration (FDA) granted Fast Track designation to IMM-1-104, a treatment for pancreatic ductal adenocarcinoma (PDAC). The designation is intended for patients who have experienced failure after one prior line of treatment.
The FDA's Fast Track program is designed to facilitate the development and accelerate the review of drugs that treat serious conditions and fill unmet medical needs. This designation underscores the potential of IMM-1-104 to address a critical gap in the treatment of PDAC, a disease with a high mortality rate and limited therapeutic options.
IMM-1-104 is under development by Immuneering, a clinical-stage oncology company focused on advancing novel cancer therapies. The Fast Track designation is anticipated to provide opportunities for more frequent interactions with the FDA during the drug development process, potentially leading to a faster path to market.
The stock experienced a 13% increase in premarket trading following the announcement, reflecting investor confidence in the potential of IMM-1-104. This regulatory milestone represents a significant step forward in Immuneering's efforts to develop innovative treatments for challenging cancers.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AVITA Medical's RECELL GO mini Receives FDA Approval for Smaller Wound Treatment

AVITA Medical's RECELL GO mini has been approved by the FDA for treating smaller full-thickness skin defects, up to 480 square centimeters.
The RECELL GO mini utilizes the same processing device as the standard RECELL GO but with a modified cartridge optimized for smaller skin samples, reducing waste.

FDA Approves Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma

The FDA has granted approval to Checkpoint Therapeutics' Unloxcyt (cosibelimab-ipdl) for the treatment of advanced cutaneous squamous cell carcinoma (cSCC).
Unloxcyt, a PD-L1 antibody, represents Checkpoint Therapeutics' first FDA-approved drug, marking a significant milestone for the company.

Replimune's RP1 Receives Priority Review from FDA for Advanced Melanoma

Replimune's BLA for RP1 in combination with Bristol Myers Squibb’s Opdivo to treat advanced melanoma has been accepted and granted priority review by the FDA.
The FDA's decision on the RP1/Opdivo combo is anticipated by July 22, 2025, with no advisory committee meeting planned currently.

Imugene's VAXINIA Shows Sustained Complete Response in Bile Tract Cancer Patient

Imugene's VAXINIA (CF33-hNIS) demonstrates a complete response in a bile tract cancer patient for over two years in the Phase 1 MAST trial, highlighting its potential efficacy.
The Bile Tract Cancer Expansion part of the MAST trial has cleared its first cohort with no dose-limiting toxicities, allowing for full enrollment of up to 10 patients.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.
The Phase III trial demonstrated that 75.9% of participants treated with Ameluz-PDT achieved complete histological clearance, versus 19% in the placebo group.

FDA Lifts Partial Hold on Avidity Biosciences' Myotonic Dystrophy Drug, Stock Surges

The FDA has lifted a partial clinical hold on Avidity Biosciences' delpacibart etedesiran (AOC 1001), a drug targeting myotonic dystrophy type 1, allowing patient recruitment for the Phase 3 trial to resume.
Following the FDA's decision, Avidity Biosciences' stock (RNA) experienced a 0.53% increase, reaching $47.30, signaling positive investor response to the advancement of AOC 1001.

Summit Therapeutics' Lung Cancer Drug Ivonescimab Receives FDA Fast Track Designation

Summit Therapeutics' stock experienced a surge following the FDA's Fast Track designation for its lung cancer drug, ivonescimab, indicating accelerated review potential.
The company has completed enrollment for a Phase 3 trial of ivonescimab, involving patients across North America, Europe, and China, marking its first global study.

Zydus Life Receives US FDA Approval for Enzalutamide Capsules in Prostate Cancer Treatment

Zydus Lifesciences secures US FDA approval for Enzalutamide capsules, a key medication in treating metastatic castration-resistant prostate cancer.
The approved drug, with an estimated annual sales of $869.4 million in the US, will be manufactured at Zydus' facility in Moraiya, Ahmedabad.

MAIA Biotechnology's Shares Surge Following FDA Approval of Telomerase Inhibitor

MAIA Biotechnology's stock increased by 14% following the FDA's approval of imetelstat, validating telomere targeting as a viable therapeutic approach.
The FDA approved Geron Corp's imetelstat for treating rare blood cancers originating in bone marrow, specifically low- to intermediate-risk myelodysplastic syndromes.

Solid Biosciences' SGT-003 Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy

Solid Biosciences' SGT-003, a next-generation gene therapy, has been granted Fast Track designation by the FDA for treating Duchenne muscular dystrophy (DMD).
The Fast Track designation aims to accelerate the development and review of SGT-003, potentially offering a substantial improvement over existing DMD therapies.

Reference News

[1]
Immuneering Shares Rise After FDA Fast-Track Status for ...
uk.marketscreener.com · Feb 20, 2024

Immuneering's stock rose 13% to $7.49 in premarket trading after receiving FDA fast-track designation for IMM-1-104, a t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy